About Black Diamond Therapeutics (BDTX)

Black Diamond Therapeutics Inc (BDTX) is a biopharmaceutical company focused on developing precision medicines for patients with genetically defined cancers. The company utilizes its proprietary Mutation-Allostery-Pharmacology (MAP) platform to discover and develop small molecule therapies that target oncogenic driver mutations. By targeting specific genetic alterations present in tumors, Black Diamond aims to develop personalized medicines that can effectively treat individual patients. The company's lead product candidate, BDTX-189, is currently in clinical development for the treatment of patients with advanced solid tumors. BDTX-189 is designed to selectively target a range of genetic alterations, including multiple BRAF and EGFR mutations, which are known to drive tumor growth in certain cancer types.

In addition to its clinical pipeline, Black Diamond is also engaged in preclinical research to identify and develop new therapies. The company's MAP platform allows for the rapid identification of allosteric mutations, which can be targeted with small molecules to inhibit tumor growth. By targeting allosteric mutations, Black Diamond aims to overcome resistance mechanisms that commonly arise with traditional targeted therapies. The company's research efforts are focused on identifying novel allosteric mutations in oncogenes that have been historically difficult to target, such as KRAS and MYC. Black Diamond believes that targeting these mutations could potentially lead to breakthrough therapies for patients with challenging-to-treat cancers.